
Phylogica licenses peptides to UK company to develop cancer drugs
Phylogica (ASX:PYC) has entered into a licensing agreement with UL biotech PhoreMost Limited to identify and develop small molecule cancer drugs.
Under the agreement Phylogica has granted PhoreMost a world-wide non-exclusive licence to use certain Phylomer libraries solely for phenotypic screening to identify novel targets involved in diseases such as cancer and then to identify and develop small molecule drugs against these targets.
In return Phylogica will be granted a 7.5% stake in PhoreMost and the rights to develop therapeutic Phylomer peptides discovered from PhoreMost screens.
This has the potential to feed Phylogica’s peptide-based oncology pipeline and unlock significant value in Phylomer platform.
Proactive Investors Australia is the market leader in producing news articles and research reports on ASX emerging companies with distribution in Australia UK North America and Hong Kong / China.

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- Rank Platform Officially Announces TGE And $RAN Listing On MEXC
- PU Prime X AFA Launch Official Football Giveaway
- Bydfi Joins Seoul Meta Week 2025, Advancing Web3 Vision And South Korea Strategy
- David Kinitsky Joins Everstake As CEO To Drive Institutional Growth, Investment And Global Expansion
- NEXST Launches Web3 VR Entertainment Platform With K-Pop Group UNIS As First Global Partner
- G-Knot Appoints Fintech, Crypto Veteran Wes Kaplan As CEO To Launch The First Finger Vein Biometric Wallet
Comments
No comment